Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 6/20 | 0.47 |
| ▸ | CCNC | P24863 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.44 |
| ▸ | GRK5 | P34947 | 1/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30845796 | 0.90 | GRM2 (0.49) | PIK3CGCHEK1FYNCCNCCDK8 | |
| SCHEMBL21033576 | 0.84 | KDM4E (0.60) | PIK3CGCHEK1FYNRIPK1 | |
| SCHEMBL21033570 | 0.80 | FYN (0.42) | PIK3CGCHEK1FYNGRK5RIPK1 | |
| SCHEMBL21033166 | 0.77 | USP30 (0.55) | PIK3CGCHEK1CCNCCDK8PIM1 | |
| SCHEMBL16598687 | 0.76 | KDM4E (0.48) | CSNK1DCSNK1E | |
| SCHEMBL3498169 | 0.76 | KMO (0.47) | — | |
| SCHEMBL21033340 | 0.76 | CHEK1 (0.47) | CHEK1FYNCCNCCDK8STING1 | |
| SCHEMBL22534369 | 0.76 | STING1 (0.60) | CHEK1FYNCCNCCDK8STING1 | |
| SCHEMBL21033209 | 0.75 | KDM4E (0.39) | CDK8CSNK1DCSNK1E | |
| SCHEMBL21033225 | 0.75 | CHEK1 (0.50) | PIK3CGCHEK1FYNCCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| WO-2019102494-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PIK3CG 3484/4885CHEK1 527/4885FYN 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.